Key points from article :
CELLVIE closes a $5.5 Million financing to get Series A-ready by the end of 2023.
Cash will accelerate the development of the company’s technology platform, strengthening the team.
cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria
Therapeutic Mitochondria Transplantation (TMT) can reinvigorate the cell energy metabolism.
"... we have focused our efforts over the past two years on scalable productization – developing an allogeneic off-the-shelf product" - Dr. Alexander Schueller (co-founder and CEO of cellvie).
Taiho Ventures LLC joins Kizoo Technology Capital as one of cellvie’s primary investors.
“We see great potential in the therapeutic use of mitochondria, particularly in the fight against cancer" - Sakae Asanuma (President and CEO of Taiho Ventures LLC).
Kizoo lead the company’s seed round in 2020.
